At its September 10th meeting, the Maryland Prescription Drug Affordability Board (PDAB) approved its upper payment limit (UPL) action plan and updated its cost review regulations.
Before the approval, the Board reviewed key themes from public comments, including suggestions to delay the UPL process, calls for greater specificity in the criteria and procedures, and concerns about unintended consequences, confidential data, and the impact on the drug supply chain. The Board emphasized the extensive groundwork already completed by the Board over the past year, suggesting that further delays were unnecessary, and noted that each drug requires a unique analysis. With these considerations, the Board formally adopted the UPL action plan. The next step involves submitting the plan to the legislative committee for approval, followed by the development of regulations to govern the process to set UPLs.
In addition, the Board adopted revisions to emergency regulations (COMAR 14.01.04.05). The revisions clarified data sources, included additional factors for consideration in cost reviews, and updated the regulations to align with the UPL action plan.
The Board also approved an agreement with the University of Maryland School of Pharmacy for drug reviews and analysis. The Board’s next regularly scheduled meeting will be on October 28, 2024.
View supply chain report. View UPL action plan. View cost review regulations. View meeting slides and other materials.
Last Updated on October 14, 2024 by Aimed Alliance
